Evaluating long-term effects of osseointegrated devices on hearing and cognition

Pilot Study to Evaluate the Long-term Chronic Care of Patients Who Could or do Utilize an Osseointegrated Device (OID)

University of South Florida · NCT04899037

This study is trying to see how using special hearing devices affects the thinking and daily life of people with hearing loss over three years.

Quick facts

Study typeObservational
Enrollment50 (estimated)
Ages18 Years to 85 Years
SexAll
SponsorUniversity of South Florida (other)
Locations1 site (Tampa, Florida)
Trial IDNCT04899037 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess the long-term cognitive and functional outcomes of patients with hearing loss who utilize osseointegrated devices (OID) compared to those who do not. Participants aged 18-85 will be followed for three years to evaluate changes in global cognitive function, hearing performance, quality of life, and social interactions. The study will focus on individuals with conductive, mixed, or unilateral hearing loss and will analyze the impact of OID intervention on various secondary outcomes. The research seeks to fill gaps in understanding the relationship between hearing interventions and cognitive decline.

Who should consider this trial

Good fit: Ideal candidates are community-dwelling adults aged 18-85 with specific types of hearing impairment who are fluent in English and at risk for cognitive decline.

Not a fit: Patients with significant disabilities in daily living activities or those with substantial cognitive impairment may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide insights into how osseointegrated devices may improve cognitive function and quality of life for patients with hearing loss.

How similar studies have performed: While there is limited research specifically on osseointegrated devices and cognitive outcomes, similar studies have shown promising results in the relationship between hearing interventions and cognitive health.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* age 18-85 years
* community dwelling
* residency: participants must plan to reside in the local area for the study duration.
* fluent English-speaker
* Audiometric hearing impairment: participants must have hearing configuration that could benefit from OID hearing intervention.
* Mini-Mental State Exam (MMSE) score \> 23 for individuals with high-school degree or less; Mini-Mental State Exam (MMSE) score \>25 for individuals with some college or more; participants must be at risk for cognitive decline the range quantified well by neurocognitive testing, and so must be free from more substantial cognitive impairment at baseline.
* willingness to participant and adhere to the protocol: participants must be willing and able to consent to participate in the study and be willing to commit to adhere to the study protocol for the duration of the study (3 years)

Exclusion Criteria:

* self-reported disability in \>2 or more Activities of Daily Living (ADL)
* medical contraindication to use of OID; because OIDs will be the primary device used in the hearing intervention, participants with medical contraindications to OID use are excluded

Where this trial is running

Tampa, Florida

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Hearing Loss, Conductive, Hearing Loss, Mixed, Deafness, Unilateral, osseointegrated device, cognition, hearing loss, neurocognitive, BAHA

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.